Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 14/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242942 | 0.99 | KCNA5 (1.00) | KCNA5KCNH2MEN1KMT2AKDM4E | |
| SCHEMBL1242083 | 0.97 | KCNA5 (1.00) | KCNA5KCNH2MEN1KMT2AKDM4E | |
| SCHEMBL1243261 | 0.92 | KCNA5 (0.87) | KCNA5KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1242194 | 0.87 | KCNA5 (0.78) | KCNA5KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1242917 | 0.82 | KCNA5 (0.79) | KCNA5KCNH2ALDH1A1 | |
| SCHEMBL1243073 | 0.79 | KCNA5 (1.00) | KCNA5KCNH2ALDH1A1 | |
| SCHEMBL1242050 | 0.78 | KCNA5 (0.76) | KCNA5KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1242858 | 0.76 | KCNA5 (1.00) | KCNA5KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1240366 | 0.73 | KCNA5 (1.00) | KCNA5KCNH2ALDH1A1 | |
| SCHEMBL9902767 | 0.73 | KCNA5 (0.93) | KCNA5KCNH2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNA5 11/4885KCNH2 3/4885MEN1 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.